CFMG & Wellpath in California — a documentary investigation · Article 013 of 100 · Series 2 — Inside the management agreement

The Company Designee: The Little-Studied Office at the Center of CFMG Approval

Published

20 September 2026, 6:00 PM PT

Content last changed

25 September 2026

Public-evidence cutoff

25 September 2026

Sources checked

25 September 2026

Record through

25 September 2026

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

The Company Designee: The Little-Studied Office at the Center of CFMG Approval turns on the difference between authority written on paper and authority demonstrated in operation. The analysis reads the management-services architecture as a division of functions, then tests whether the economic and administrative structure supports, constrains, or leaves unanswered the professional authority formally reserved to CFMG.

The governing question is narrow: Who could speak for CFMG under the MSA, and why does the missing appointment history matter? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

II. Structural and Historical Context#

III. The Control and Governance Analysis#

Why California law makes that distinction important#

The Medical Board of California says the state’s corporate-practice doctrine is intended to prevent unlicensed persons from interfering with physician professional judgment. Its current guidance identifies decisions such as diagnostic testing, referrals, ultimate patient care, physician workload and hours, clinically related hiring or firing, medical-record control, coding and billing, and medical-equipment decisions as areas in which physician authority matters. The Board says an MSO may be consulted, but the licensed physician must retain ultimate responsibility or approval for decisions that cannot be delegated. Source: Medical Board of California

That does not mean a large MSO is inherently unlawful.

It means the boundary matters .

2018: Correct Care Solutions and CMGC combine#

On October 1, 2018, H.I.G. announced that one of its affiliates had acquired Correct Care Solutions and combined it with its existing portfolio company, Correctional Medical Group Companies.

H.I.G. described CMGC as having been founded in 1983 “as California Forensic Medical Group.” It described the new CCS-CMGC enterprise as a national provider operating across correctional and behavioral-health settings. H.I.G., Oct. 1, 2018

This is an important enterprise-level event.

It should not be overread as proof that the California professional corporation legally merged out of existence.

The statutory foundation#

California Business and Professions Code §2400 states, subject to statutory exceptions, that corporations and other artificial entities have no professional rights, privileges or powers. BPC §2400

Business and Professions Code §2052 prohibits the unlicensed practice of medicine and addresses persons who aid or assist unlicensed practice. BPC §2052

California simultaneously permits professional corporations organized under its professional-corporation statutes. Corporations Code §13401.5 identifies categories of licensed professionals who may participate in specified professional corporations and limits the aggregate ownership of certain non-physician licensed professionals in a medical corporation. Corporations Code §13401.5

The practical result is not “corporations cannot be involved in healthcare.”

It is that California draws a line between:

• a professional corporation through which licensed professionals exercise professional powers; and

• a management organization that may provide administrative infrastructure without taking the professional powers for itself.

The “last word” test#

The Medical Board’s guidance says that while physicians may consult unlicensed persons regarding relevant management decisions, the physician must retain ultimate responsibility or approval for the decisions that cannot be delegated.

That gives this investigation a practical test.

For any disputed function, ask:

• Who identified the issue?

• Who gathered the information?

• Who made the recommendation?

• Did a licensed physician independently review it?

• Who had authority to approve, reject or modify the recommendation?

• Who implemented the result?

• What happened when management and physician leadership disagreed?

The identity of the person who sends the email or changes the computer status may not answer the question.

The legally important actor may be the person who possessed the final veto.

Why physician workload belongs in the analysis#

One of the most significant parts of the Medical Board’s guidance is its express treatment of workload.

The Board lists both:

• how many patients a physician must see; and

• how many hours a physician must work

as physician decisions.

That matters in correctional healthcare because staffing, census, contractual service levels and custody operations can all influence workload.

An investigation therefore has to distinguish among:

• a County’s contractual staffing requirement;

• an MSO’s workforce recommendation;

• a professional corporation’s physician-staffing decision;

• and an individual physician’s patient-specific clinical judgment.

Those are different sources of authority.

Records, coding and equipment are not merely back-office subjects#

The same point applies to systems that may look administrative.

A management company can provide recordkeeping technology.

But the Board treats substantive control of medical records as a physician issue.

A management company can process billing.

But the Board identifies coding and billing procedures as an area of physician control.

A management company can procure equipment.

But the Board includes approval of medical equipment and supplies in its physician-control guidance.

The analysis therefore turns on the difference between administration and final substantive authority .

Layer one: explicit professional independence#

The agreement begins with formal safeguards.

It describes the parties as independent contractors. It says CFMG is solely and exclusively in control of professional medical services and says the management company will not control the methods by which physicians practice medicine.

It also states that the manager will not provide a service that would itself constitute clinical practice or professional medical services.

Those provisions are substantial evidence of the intended legal allocation .

They should not be dismissed merely because the same contract contains extensive management powers.

At the same time, formal language is not proof of how every later decision actually operated.

That distinction — intended allocation versus actual practice — is the central theme of this investigation.

Layer two: an exclusive management relationship#

The agreement makes the management company CFMG’s exclusive provider of management services .

The manager is authorized to perform those services in the manner it considers reasonably appropriate to meet the day-to-day business needs of CFMG, subject to the agreement and applicable law.

This is not a narrow payroll contract.

Exhibit B describes a broad operating platform.

Among the functions assigned to the manager are categories involving:

• legal and regulatory support;

• accounting and finance;

• payroll and tax administration;

• benefit-plan administration;

• administrative personnel;

• information technology;

• database and connectivity services;

• electronic medical-record implementation and maintenance;

• insurance and risk management;

• billing and collections;

• record-maintenance infrastructure;

• supplies and support services;

• purchasing;

• marketing and bidding assistance;

• and office support.

The correct conclusion is straightforward:

The contract contemplated extensive administrative integration from the beginning.

That does not answer who had final professional authority.

Layer three: the Company Designee#

One of the most important governance provisions appears early in the agreement.

When the contract calls for CFMG approval, consent, direction or other action — unless the agreement says otherwise — action by the person designated as CFMG’s chief executive officer under its bylaws, termed the Company Designee , can constitute action by CFMG.

The agreement also provides for a management-company representative to attend and participate in certain meetings involving the Company Designee and equityholders, in a non-voting capacity.

This is a governance-adjacent mechanism.

It proves that the management relationship reached beyond isolated back-office tasks.

It does not prove that the manager had a vote or could compel a professional decision.

The public investigation therefore needs to identify:

• who served as Company Designee over time;

• what authority CFMG’s bylaws gave that role;

• and what categories of decisions moved through that approval channel.

Layer five: professional functions assigned to CFMG#

Section 3.4 assigns CFMG responsibility, in consultation with the manager, for several functions near the heart of professional governance.

These include:

• utilization review and quality-assurance guidelines;

• physician documentation;

• physician corrective action;

• credentialing physicians for specific procedures;

• handling impaired physicians;

• and policies of a purely medical nature.

The contract therefore does not simply say “CFMG handles medicine” in general terms.

It identifies particular areas where CFMG is supposed to remain responsible.

For the public investigation, those categories become testable domains.

It does not prove#

• that every formal safeguard was followed in practice;

• that the management company actually overrode CFMG physicians;

• that CFMG exercised an independent veto in every relevant event;

• that Wellpath owned CFMG professional-corporation shares;

• what the stock-transfer restrictions actually provided;

• or that the structure violated California law.

Those conclusions require evidence beyond the contract.

California Forensic Medical Group, Inc. (CFMG)#

The central California professional corporation. Current evidence strongly supports continuing legal existence, County-contract significance, employer identity in important labor/wage records, physician corporate governance, and litigation significance.

What is established:

• distinct juridical existence;

• professional-corporation status;

• continued current contracting/employer roles;

• physician officers/directors;

• formal professional authority under the MSA.

What is not established:

• exact current shareholder roster;

• exact historical share percentages;

• exact CFMG stock-transfer terms;

• who can compel transfer or replacement of physician ownership.

Master reader orientation#

The final project conclusion is not that CFMG and Wellpath are “the same entity,” nor that they are operational strangers.

The record supports a layered model:

• CFMG — legally distinct California professional corporation; formal County contractor and strong formal physician-employer evidence; claimed physician-governance authority.

• Wellpath / management entities — extensive MSO/enterprise infrastructure across HR, systems, compensation, credentialing administration, finance, claims, records, litigation, and other operational domains.

• County/client authority — an independent source of contract, security, access, transportation, remedial-plan, and operational requirements.

• Individual licensed clinicians — patient-specific professional judgment and other physician-reserved functions.

The final unresolved issue is function-specific:

When an administrative process reached a decision California reserves to physicians, who possessed practical final approval or veto, and what happened when CFMG and Wellpath disagreed?

Cfmg's termination rights are real, but narrowly structured#

Section 5.2 permits CFMG to terminate immediately if the management company materially breaches the MSA, fails to cure within 45 days after written notice, and the breach materially adversely affects CFMG.

The required notice must be executed by the Company Designee to be effective.

CFMG can also terminate if the management company enters specified insolvency proceedings.

This is meaningful termination authority.

It is evidence against an assertion that CFMG had literally no contractual exit right.

But several structural features narrow that freedom.

First, the agreement does not appear to provide CFMG a broad termination-for-convenience right during the term.

Second, CFMG's breach notice must come from the Company Designee.

Third, the management company has its own termination rights.

Fourth, termination of the Deficit Funding Loan Agreement gives the management company an immediate termination right under the MSA.

Fifth, certain breaches can trigger substantial payment consequences.

Accordingly, the proper question is not whether CFMG had some termination right.

It is:

Could the physician corporation realistically choose a new MSO simply because its physicians preferred a different manager?

On the current text, that proposition is not established.

The company-designee mechanism can concentrate CFMG corporate authority#

Section 1.4 of the MSA provides that when CFMG approval, consent, direction, or action is required, the action of the person designated as CFMG's Chief Executive Officer under its bylaws—the Company Designee —constitutes action of CFMG unless otherwise specified.

The management company may assume that required internal CFMG consents and approvals have been obtained.

This can be a commercially efficient agency mechanism.

But it can also become an evidentiary bottleneck.

If extensive CFMG corporate authority passed through one physician officer, the critical questions become:

• who held the Company Designee role each year;

• whether that person was a shareholder;

• whether that person held roles on the Wellpath/MSO side;

• what independent information the designee reviewed;

• whether board/shareholder deliberation occurred;

• whether the designee ever rejected management recommendations.

A structure can be formally physician-controlled while still concentrating all practical PC approval in one physician officer.

That is not automatically unlawful.

It does mean the independence of that office is central.

Company Designee#

The 2012 MSA creates a separate contractual concept.

Section 1.4 provides that the person designated as CFMG's Chief Executive Officer under its bylaws is the Company Designee and, unless otherwise specified, that person's approval, consent, direction, or action constitutes CFMG action.

This role is exceptionally consequential.

A Company Designee may be the practical corporate bottleneck through which large portions of the CFMG–MSO relationship operate.

the record therefore needs a Company Designee chronology , not merely a president chronology.

Dan hustedt may have been the original "company designee" — but that remains an inference#

Section 1.4 of the MSA defines the Company Designee as the person designated as CFMG's Chief Executive Officer under its bylaws.

The signature page identifies Dan Hustedt as CFMG's CEO.

It is therefore reasonable to infer that he appears to fit the contractual definition of Company Designee at execution .

But this should not be published as a definitive fact without the bylaws or formal designation record.

That distinction matters because the Company Designee could act for CFMG under much of the MSA and the manager could assume that necessary internal approvals had been obtained.

The identity of the Company Designee at each point in time may ultimately be more important than the identity of the president.

Wellpath’s Chapter 11 case is the strongest natural experiment yet for testing the CFMG–Wellpath relationship.

The reason is straightforward.

Before bankruptcy, extensive operational integration could coexist with imprecise nomenclature because there was often little immediate reason for counties, clinicians, litigants, or courts to distinguish the professional corporation from the management enterprise with precision.

Bankruptcy changed that.

Once Wellpath entered Chapter 11:

• debtor and nondebtor status mattered;

• property of the estate mattered;

• executory-contract rights mattered;

• insurance and indemnity mattered;

• ownership and contract rights mattered;

• the identity of the professional corporations mattered;

• the ability to continue management relationships mattered;

• and the transition from H.I.G.-sponsored ownership to lender ownership mattered.

The bankruptcy record therefore forced Wellpath to explain its professional-corporation architecture in pleadings filed before a federal bankruptcy court.

The result is unusually revealing.

Wellpath’s own November 12, 2024 Professional Corporation Motion described the nationwide structure as a “friendly professional corporation” structure . The Debtors said the professional corporations were owned exclusively by licensed physicians affiliated with the Debtors , while the Debtors exercised certain control over the nonclinical business-management and administrative functions. At the same time, the Debtors disclosed that:

• the 18 professional corporations collectively generated more than $674 million in 2023 revenue “for the benefit of the Debtors” ;

• the Debtors and certain physician owners were parties to Stock Transfer Agreements restricting transfer of professional-corporation stock;

• those restrictions were intended not only to maintain state-law compliance and continuity of care but also to preserve the continuation of administrative services by the Debtors ;

• under those Stock Transfer Agreements, the Debtors had authority to ensure that the professional corporations remained duly licensed and qualified;

• in 2023 the Debtors remitted approximately $720 million to physician owners and vendors as professional-corporation operating costs;

• the Debtors collected certain professional-corporation receivables and deposited them into professional-corporation accounts;

• the Debtors considered the professional-corporation relationships indispensable to the success of their own reorganization.

Most strikingly, the same motion later said that the Debtors “maintain an interest in the Professional Corporations” and referred to revenue derived pursuant to the Debtors’ “ownership interests in the Professional Corporations.”

That latter language is facially difficult to reconcile with the same pleading’s statement that the professional corporations were owned exclusively by licensed physicians .

this record does not treat that wording as proof that Wellpath owned CFMG stock.

The phrase may reflect:

• imprecise bankruptcy advocacy;

• an economic or contractual “interest” rather than stock ownership;

• differences among the 18 professional corporations;

• or drafting shorthand that did not carefully distinguish equity from contractual rights.

The court did not conduct a trial determining that Wellpath owned CFMG.

But the wording is too important to ignore.

It creates one of the strongest internal-document contradictions found in this investigation and sharply increases the importance of the actual CFMG stock-transfer agreements.

The 2012 management-agreement baseline#

Earlier articles in this series identified the December 31, 2012 Management Services Agreement as the central structural instrument in the modern CFMG–MSO arrangement.

The reviewed project record attributes to that agreement several provisions favoring a lawful PC–MSO architecture:

• CFMG and the management organization are described as separate entities;

• CFMG formally employs or engages physicians;

• professional medical services and medical judgment are reserved to CFMG;

• the management organization is not itself to practice medicine or assume direct patient-care responsibility;

• broad administrative services are delegated to the management side.

The same record describes the management organization as having extensive responsibilities concerning:

• payroll and benefits administration;

• physician-employment documentation;

• HR support;

• staffing analysis;

• compensation administration and recommendations;

• billing and coding support;

• IT and electronic-record systems;

• insurance and risk;

• litigation support;

• contracting;

• purchasing and equipment;

• finance, banking, and budgeting;

• and participation in governance-related processes.

A project submission that reviewed the executed agreement also identifies a potentially important “Company Designee” mechanism, under which certain CFMG actions or approvals may be communicated through a designated CFMG officer or designee and relied upon by the management organization as CFMG action.

That mechanism is not inherently improper. But it makes authentication of the approval chain essential. If CFMG decisions were routinely transmitted through one designee, the investigation must know:

• who held that role at each relevant time;

• whether the designee was a licensed physician;

• what authority had been delegated;

• whether professional decisions could be delegated at all;

• what record showed the underlying physician decision;

• and whether the MSO could act without obtaining a fresh CFMG approval.

The MSA therefore provides the formal hypothesis. the prior analysis tests whether actual conduct matched it.

Evidentiary caution: the standalone executed 2012 MSA has not yet been separately indexed in the current saved Library under an obvious filename. the investigation's existing section-by-section crosswalk should be treated as a strong retrieval guide, while the executed agreement, exhibits, assignments, amendments, and designee records remain Tier-One authentication targets.

Medical director authority — title is not enough#

The term “Medical Director” can conceal several legally different roles.

A physician may be:

• a site medical director for the Fresno County jail;

• a regional medical director;

• a national Wellpath physician executive;

• a CFMG officer or director;

• an MSO-employed physician providing management services;

• a member of a CFMG physician board;

• a credentialing or quality reviewer;

• or some combination of those roles.

the investigation must therefore stop treating “medical director” as a self-executing answer to control.

For every physician leader involved in a disputed event, the record should identify:

• employing entity;

• corporate office, if any;

• California license status;

• written appointment;

• written delegation;

• reporting line;

• scope of clinical authority;

• scope of HR authority;

• authority to bind CFMG;

• authority to approve or reject Wellpath recommendations;

• authority over privileging/credentialing;

• authority over peer review and section 805 reporting;

• authority over physician schedules and patient volume;

• authority over referral/utilization disputes;

• and evidence of actual exercise of those powers.

Dr. Dheeraj Taranath's April 2025 communication is especially relevant. He described Wellpath as the management services organization contracted to provide the “full range of administrative services” to CFMG and represented that matters raised by the physician had been reviewed with CFMG leadership and that Wellpath communications proceeded with CFMG leadership's knowledge and approval.

That communication supports two competing inferences.

Defense inference: Wellpath was operating as an MSO and took recommendations to CFMG leadership, which retained approval.

Investigative inference: Wellpath may have functioned as the practical decision engine, with CFMG leadership providing approval after recommendations had already been developed.

The distinction cannot be resolved from phrasing alone. The underlying approval records are needed.

Company Designee records#

Prior volumes identify the MSA's “Company Designee” mechanism as a potentially important bottleneck. the prior analysis requires the actual appointment trail.

Seek:

• each Company Designee appointment;

• date effective;

• appointing authority;

• scope;

• amendments;

• revocations;

• identity/employer of designee;

• whether the designee could approve physician-employment documents;

• whether professional decisions were excluded;

• examples of designee use.

The critical issue is whether an administrative designee could transmit or formalize CFMG action versus independently make a protected professional decision.

Why an override census is more probative than a control narrative#

The phrase “who controlled CFMG?” is too broad to be useful without identifying the function, time, site, and decision.

A professional corporation can lawfully delegate or outsource administrative implementation while retaining protected professional authority. A management organization can also influence outcomes without formally owning the professional decision. The only reliable way to distinguish the two is to reconstruct concrete events.

For each event the record now asks:

• What triggered the decision?

• Who opened the workflow?

• Who developed the factual record?

• Who recommended an outcome?

• Was a professional review required?

• Which licensed physician or physician body performed that review?

• Could that reviewer reject the recommendation?

• Did the reviewer ever ask questions, delay action, impose conditions, modify reasoning, dissent, or say no?

• Who entered the final decision into the operational system?

• Did implementation occur before or after professional approval?

• What happened when the professional and administrative participants disagreed?

The last question is the most valuable.

If Wellpath recommends termination and a CFMG physician body rejects termination, and the physician remains employed, the event strongly supports practical CFMG veto power. If Wellpath proposes a workload target and a CFMG medical director reduces it for safety reasons, and the reduced target governs despite financial cost, that is strong evidence of professional independence. If a Wellpath utilization mechanism initially denies an outside referral and a CFMG physician reverses the denial, that can show physician authority over patient-specific care.

The reverse matters too. If a CFMG physician rejects an administrative recommendation but Wellpath proceeds anyway, or if Wellpath implements a clinically sensitive action before any CFMG physician review, that would weigh in the opposite direction.

Routine concurrence has much less discriminatory value. A physician can agree with an MSO recommendation for legitimate reasons. A long series of unanimous decisions proves little unless the record also shows that disagreement was practically possible.

B. The MSA creates structural dependence even while reserving professional judgment#

The control theory gives full credit to the MSA's professional-independence clauses.

Then it asks whether the rest of the architecture made independent exercise difficult in practice.

Potentially significant features identified in the investigation include:

• exclusive management;

• management participation in governance meetings;

• Company Designee mechanics;

• financial administration;

• bank-payment rights;

• broad security interests;

• staffing analysis;

• physician compensation administration;

• records and IT systems;

• employment-document administration;

• related stock-transfer restrictions referenced in assignment documents.

None independently proves CPOM.

Together they justify investigation of practical dependency.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The strongest contrary evidence is the MSA's explicit reservation of professional authority and real termination rights. The article must distinguish structural leverage from proof of an actual unlawful medical decision.

Art Center Holdings#

In April 2026, Attorney General Rob Bonta announced an amicus brief in Art Center Holdings, Inc. v. WCE CA Art . The Attorney General’s public statement emphasized that MSOs may provide administrative and back-office support but cannot own or operate medical practices or exercise undue influence over licensed medical professionals. California DOJ — Apr. 1, 2026

The analysis also focuses attention on contractual rights affecting physician ownership and owner replacement.

That is an important legal lens.

It is not a final appellate holding that every similar contractual feature is unlawful, and it is not evidence that CFMG has the same ownership provisions.

What this legal framework does not prove#

Nothing on this page establishes that:

• Wellpath unlawfully practiced medicine;

• CFMG failed to exercise professional independence;

• a particular management function violated §2400;

• a particular shareholder arrangement was unlawful;

• or a regulator or court has adjudicated the CFMG–Wellpath structure unlawful.

Those are factual and legal conclusions that require CFMG-specific evidence.

The purpose of the framework is to identify what evidence would matter.

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include Company Designee history, practical MSO replacement, compensation veto, and an actual event where formal professional authority changed management's preferred outcome.

Current evidence supporting deeper structural-control investigation#

The strongest contrary or investigative facts include:

• Wellpath/MSO is the exclusive manager.

• The original term was ten years, with five-year automatic renewals.

• CFMG lacks an obvious broad termination-for-convenience right in the public MSA.

• Management receives notice of and can participate in all covered CFMG shareholder/Company Designee meetings.

• Failure to provide required meeting notice can support manager termination.

• CFMG action can be concentrated through one Company Designee.

• CFMG cannot assign the MSA without manager consent.

• Manager can freely assign without CFMG consent.

• The 2019 assignment transferred related stock-transfer restriction agreements.

• Management fee begins at 18% of adjusted gross revenue.

• Manager may cause disbursement from CFMG accounts, including advances before due date.

• CFMG grants a broad security interest in its assets to secure amounts owed.

• CFMG may be financially dependent on manager advances under the Deficit Funding Loan Agreement.

• Manager may terminate the MSA when the Deficit Funding Loan Agreement terminates.

• Certain termination scenarios accelerate management fees for the remainder of the term.

• Personnel restrictions may affect CFMG's ability to recreate management infrastructure after exit.

• Manager-side financing links the CFMG payment stream to collateral-agent arrangements.

• Current stock-transfer/succession instruments remain undisclosed in the public corpus.

These facts still do not establish unlawful control.

They establish why the missing instruments have unusually high evidentiary value.

CFMG Shareholders, Directors, Officers, Company Designees, Stock Succession, Cross-Roles, and the Search for the Missing Stock-Transfer Agreements#

the prior analysis establishes why ownership succession is the top unresolved structural issue.

the prior analysis should reconstruct:

• every identifiable CFMG shareholder;

• every president/CEO/secretary/CFO;

• every Company Designee;

• overlap with CMGC/Wellpath roles;

• corporate signature history;

• death/resignation/retirement succession events;

• public filings and county contracts;

• historical H.I.G./CMGC transaction representations;

• the most likely repositories for the missing stock agreements.

Only after that chain is reconstructed should the investigation draw any conclusion about who ultimately controlled CFMG ownership.

After six volumes, the most important remaining structural question is ownership.

This article produces a significant clarification:

The public record now permits a reasonably strong reconstruction of CFMG's corporate officers and directors over time, but it still does not identify the current CFMG shareholders or their percentages with sufficient reliability.

That distinction is critical.

A person can be:

• a physician;

• an officer;

• a director;

• a president;

• a chief executive officer;

• a Company Designee under the MSA;

• a medical director;

• a Wellpath executive;

• and even the person signing CFMG contracts

without necessarily being a shareholder.

Conversely, a shareholder may hold no public operating title.

Accordingly, officer succession cannot be treated as proof of stock succession .

The strongest current governance evidence is:

• the 2012 MSA;

• county contracts signed under California corporate formalities;

• California Secretary of State Statements of Information;

• federal litigation;

• labor agreements;

• the Wellpath bankruptcy;

• Wellpath public corporate materials.

Those records establish who held many formal offices.

They do not disclose the stock ledger.

The stock-transfer restriction agreements expressly referenced in the 2019 assignment therefore remain the single most important missing ownership source.

K. Ownership and succession remain the most important unresolved structural issue#

the prior analysis established that the 2019 assignment transferred the CFMG MSA together with related instruments expressly including relevant stock-transfer restriction agreements.

The enterprise bankruptcy record independently described Wellpath’s friendly-PC model as using stock-transfer agreements to manage ownership succession and qualification.

But the CFMG-specific operative instrument has not been authenticated in the current record.

Accordingly, the investigation cannot responsibly state whether Wellpath held:

• owner nomination rights;

• approval rights;

• veto rights;

• replacement rights;

• stock options;

• proxies;

• powers of attorney;

• mandatory-transfer rights;

• rights triggered by physician employment;

• or rights tied to MSA termination.

This missing instrument is especially important after California’s 2026 enforcement focus on physician-owner replacement and MSO entrenchment.

The correct final classification is:

TIER-ONE OPEN STRUCTURAL EVIDENCE — potentially decisive, not yet proved.

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

CFMG predates Wellpath by decades#

H.I.G. Capital’s January 2013 announcement described CFMG as a California correctional-healthcare company founded in 1983 and operating across the state. H.I.G. announced that an affiliate had made a strategic investment in the company. The release identified CFMG’s then-president and medical director, Dr. Taylor Fithian, and described the company as a provider of outsourced healthcare to county jails. Source: H.I.G. Capital, Jan. 7, 2013

That announcement is important, but it should be read narrowly. It establishes an investment relationship. It does not , by itself, establish that H.I.G. directly acquired the shares of the California professional corporation or identify CFMG’s shareholder structure after the transaction.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 012 — The Other Half of the MSA: How Broad the Management Grant Really Is

• Article 014 — Who Designs the Physician Employment Contract? CFMG, Wellpath, and the Employment-Form Architecture

• Article 011 — What the MSA Actually Reserves to Physicians

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: Who could speak for CFMG under the MSA, and why does the missing appointment history matter? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are Company Designee, delegated authority, appointment history, and corporate approval. The source spine identified in the current public record is: Company Designee clauses; execution signatures; Hustedt roles; missing bylaws/appointments; later officer chronology. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

A management-services agreement must be read function by function. Administrative delegation is not synonymous with delegation of professional judgment. The evidentiary task is to identify the exact contractual reservation, the exact management power, and the real-world implementation record when those provisions came into tension. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for The Company Designee: The Little-Studied Office at the Center of CFMG Approval should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ntiary lane. Core question. Who could speak for CFMG under the MSA, and why does the missing appointment history matter?

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

Chronology as a control test#

Chronology is often more probative than organizational charts. The decisive question is not merely who possessed authority on paper, but when a decision became operative and what happened immediately before and after that moment. A later board vote, HR notice, county communication, or litigation position may confirm, ratify, or explain an earlier act without proving who made the initial decision. Conversely, an early recommendation may have no legal effect until the authorized professional or contracting entity adopts it.

For The Company Designee: The Little-Studied Office at the Center of CFMG Approval, the chronology should be reconstructed with document-level precision. Investigators should place each significant contract, amendment, email that has entered the public record, board action, personnel or agency event that is lawfully publishable, and court filing on a single timeline. Each entry should identify the actor, capacity, entity, action verb, and legal effect. Terms such as “recommended,” “approved,” “directed,” “implemented,” “ratified,” “reported,” and “terminated” are not synonyms. The wording can reveal whether a participant supplied information, exercised discretion, or merely carried out another actor's decision.

The current article supplies anchor points that should remain central. The Company Designee: The Little-Studied Office at the Center of CFMG Approval turns on the difference between authority written on paper and authority demonstrated in operation. The analysis reads the management-services architecture as a division of functions, then tests whether the economic and administrative structure supports, constrains, or leaves unanswered the professional authority formally reserved to CFMG. The governing question is narrow: Who could speak for CFMG under the MSA, and why does the missing appointment history matter? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

A robust chronology is also the best protection against overstatement. If the alleged controlling act occurred before the supposedly controlling actor entered the process, that theory weakens. If a professional body acted only after implementation, a claim that it supplied the first operative decision requires qualification. If the public record shows independent deliberation before implementation, that evidence materially strengthens the formal-independence account. The analysis therefore must treat time as an evidentiary variable, not just background narrative.

The strongest lawful explanation and the strongest investigative hypothesis#

A publication written to withstand adversarial review should state the strongest lawful explanation in full rather than burying it. The strongest conventional explanation is that a broad MSO grant can coexist with lawful physician control because nonclinical infrastructure—finance, payroll, recruiting support, benefits, IT, records, insurance, billing, and contract administration—can be centralized while professional decisions remain reserved to licensed physicians. That explanation is not a concession; it is the baseline against which any more serious inference must be tested.

The strongest investigative hypothesis must be equally disciplined. The strongest investigative concern arises where economic or administrative rights operate as practical leverage over a nominally reserved professional decision. That concern cannot be established by contract breadth alone; it requires evidence of a conflict, the sequence of communications, the available alternatives, and who controlled implementation. The hypothesis should not be written as a conclusion unless the missing bridge evidence exists. Its value is to identify the next records and witnesses that matter.

The two accounts can coexist over large portions of the record. An enterprise can be operationally integrated and legally segmented. A physician professional corporation can be genuine while depending heavily on an MSO. An MSO can provide extensive infrastructure while a physician body retains clinical authority. A county can demand staffing and quality metrics while individual clinicians retain professional duties. The legal issue arises at the boundary: who had the lawful and practical ability to decide the disputed function when interests diverged?

The analysis must resist labels such as “shell,” “alter ego,” “subsidiary,” “employer,” or “controller” unless the source and legal test support them. The more defensible phrasing is functional and dated: the record shows that a specified entity administered payroll, signed a county amendment, sponsored a benefit, chaired a committee, received a claim, or approved a clinical policy. From those proven verbs, the investigation can build—but should not skip—the legal analysis.

The California enforcement record, 2021–2026#

Owner-replacement and succession are the Attorney General’s central 2026 concern. In Art Center the Attorney General argues that an unlicensed corporation’s contractual right to replace the physician owner with a physician of its choosing can amount to effective ownership and control; Carbon Health’s complaint describes succession and option provisions of the same kind. Whether any CFMG instrument gives the management side a say in who holds or succeeds to the Company Designee or shareholder role is therefore the question this article’s evidence should be tested against.

Relevant control indicators: Owner replacement / succession; last word in disagreement. See the California control-indicator matrix in California’s Corporate-Practice Enforcement Record, 2021–2026. Added 25 September 2026.

Sources and authorities#

1. Source: Medical Board of California www.mbc.ca.gov — https://www.mbc.ca.gov/Licensing/Physicians-and-Surgeons/Practice-Information/
2. H.I.G., Oct. 1, 2018 hig.com — https://hig.com/news/correct-care-solutions-and-correctional-medical-group-companies-join-forces-to-deliver-best-in-class-healthcare/
3. BPC §2400 leginfo.legislature.ca.gov — https://leginfo.legislature.ca.gov/faces/codes\_displaySection.xhtml?lawCode=BPC&sectionNum=2400.
4. BPC §2052 leginfo.legislature.ca.gov — https://leginfo.legislature.ca.gov/faces/codes\_displaySection.xhtml?lawCode=BPC&sectionNum=2052.
5. Corporations Code §13401.5 leginfo.legislature.ca.gov — https://leginfo.legislature.ca.gov/faces/codes\_displaySection.xhtml?lawCode=CORP&sectionNum=13401.5.
6. California DOJ — Apr. 1, 2026 oag.ca.gov — https://oag.ca.gov/news/press-releases/attorney-general-bonta-files-amicus-brief-defense-california%E2%80%99s-ban-corporate
7. Source: H.I.G. Capital, Jan. 7, 2013 hig.com — https://hig.com/news/h-i-g-capital-announces-strategic-investment-in-california-forensic-medical-group/